Stock Scorer

BioNTech SE (BNTX)

BioNTech SE reported revenue of 2.9B EUR for the year ending 31 December 2025, up 4.3% from 2.8B a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in EUR. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in EUR.
FigurePeriodAmountYear on year
Revenue 2025 · ending 31 December 2025 2.9B +4.3%
Gross Profit 2019 · ending 31 December 2019 91.2M -19.9%
Operating Income 2025 · ending 31 December 2025 -1.4B —
Net Income 2025 · ending 31 December 2025 -1.1B —
Cost of Revenue 2025 · ending 31 December 2025 641.8M +18.6%
Operating Cash Flow 2025 · ending 31 December 2025 456M +119.5%
Free Cash Flow 2025 · ending 31 December 2025 280.9M —
Shares Outstanding 2025 · ending 31 December 2025 241.7M +0.5%
EPS 2025 · ending 31 December 2025 -4.70 —

Revenue and profit by financial year

As filed, in EUR. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 2.9B-1.4B-1.1B280.9M
20242024-12-31 2.8B-1.3B-665.3M-78.8M
20232023-12-31 3.8B690.4M930.3M5.1B
20222022-12-31 17.3B12.6B9.4B13.2B
20212021-12-31 19B15.3B10.3B762.2M
20202020-12-31 482.3M-82.4M15.2M-79.5M
20192019-12-31 108.6M-181.5M-179.2M-237.1M
20182018-12-31 127.6M-53.9M-48.3M-88.8M
20172017-12-31 61.6M-61.3M-86M-76.9M

Every period

Revenue Annual

PeriodEndingRevenue
FY252025-12-312.9B
FY242024-12-312.8B
FY232023-12-313.8B
FY222022-12-3117.3B
FY212021-12-3119B

Gross Profit Annual

PeriodEndingGross Profit
FY192019-12-3191.2M
FY182018-12-31113.9M
FY172017-12-3152.3M

Operating Income Annual

PeriodEndingOperating Income
FY252025-12-31-1.4B
FY242024-12-31-1.3B
FY232023-12-31690.4M
FY222022-12-3112.6B
FY212021-12-3115.3B

Net Income Annual

PeriodEndingNet Income
FY252025-12-31-1.1B
FY242024-12-31-665.3M
FY232023-12-31930.3M
FY222022-12-319.4B
FY212021-12-3110.3B

Cost of Revenue Annual

PeriodEndingCost of Revenue
FY252025-12-31641.8M
FY242024-12-31541.3M
FY232023-12-31599.8M
FY222022-12-313B
FY212021-12-312.9B

Operating Cash Flow Annual

PeriodEndingOperating Cash Flow
FY252025-12-31456M
FY242024-12-31207.7M
FY232023-12-315.4B
FY222022-12-3113.6B
FY212021-12-31889.7M

Free Cash Flow Annual

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
FY252025-12-31280.9M
FY242024-12-31-78.8M
FY232023-12-315.1B
FY222022-12-3113.2B
FY212021-12-31762.2M

Shares Outstanding Annual

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
FY252025-12-31241.7M
FY242024-12-31240.4M
FY232023-12-31242.7M
FY222022-12-31249.8M
FY212021-12-31259.7M

EPS Annual

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
FY252025-12-31-4.70
FY242024-12-31-2.77
FY232023-12-313.83
FY222022-12-3137.77
FY212021-12-3139.63